UTHR SEC फाइलिंग - United Therapeutics Corporation- वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट, प्रॉस्पेक्टस

मूलभूत आँकड़े

LEI	5299005C4HZL4UWROC14
CIK	1082554

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to United Therapeutics Corporation

SEC Filings (Chronological Order)

यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।

September 2, 2025	EX-99.1	For Immediate Release Exhibit 99.1 For Immediate Release United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis Positive results were observed across all subgroups Study meets several key secondary endpoints with statistical significance SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 2, 2025: United Therapeutic
September 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 United Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju
August 1, 2025	EX-99.1	For Immediate Release Exhibit 99.1 For Immediate Release United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program Repurchase reflects the strength of United Therapeutics’ balance sheet and confidence in its near-term prospects SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., August 1, 2025: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced that
August 1, 2025	EX-10.1	Re: Collared Accelerated Share Repurchase Exhibit 10.1 Execution Version United Therapeutics Corporation 1000 Spring Street Silver Spring MD 20910 Attention: James Edgemond, Chief Financial Officer and Treasurer Re: Collared Accelerated Share Repurchase Ladies and Gentlemen: This master confirmation (this “Master Confirmation”), dated as of August 1, 2025 is intended to set forth certain terms and provisions of certain Transactions (each,
August 1, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris
July 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 United Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commiss
July 30, 2025	EX-99.1	Three Months Ended June 30, Dollar Change Percentage Change 2025 2024 Total revenues $ 798.6 $ 714.9 $ 83.7 12 % Net income $ 309.5 $ 278.1 $ 31.4 11 % Net income, per basic share $ 6.86 $ 6.26 $ 0.60 10 % Net income, per diluted share $ 6.41 $ 5.85 Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results Record total revenue of $799 million, reflecting 12 percent growth over the second quarter of 2024 and 12 consecutive quarters of double-digit, year-over-year total revenue growth Share repurchase of up to $1 billion authorized by the Board of Directors, expiring March 31, 2026 T
July 30, 2025	EX-10.3	Eighth Amendment to Specialty Pharmacy Network Agreement, dated as of April 11, 2025, between the Registrant and Accredo Health Group, Inc. Exhibit 10.3 EIGHTH AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Eighth Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred
July 30, 2025	EX-FILING FEES	Filing Fee Table* Exhibit 107.1 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) TABLE 1 – NEWLY REGISTERED SECURITIES Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock,
July 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0
July 30, 2025	S-8	As filed with the Securities and Exchange Commission on July 30, 2025 As filed with the Securities and Exchange Commission on July 30, 2025 Registration No.
June 27, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 United Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd
June 27, 2025	EX-10.1	United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan Exhibit 10.1 UNITED THERAPEUTICS CORPORATION AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN (effective June 26, 2025) 1. Purpose The purpose of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (this “Plan”) is to advance the interests of United Therapeutics Corporation (the “Company”) by stimulating the efforts of employees, officers, non-employee directors and ot
May 30, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdiction of File Number) Identification Number) Incorporation or Organization) 1000 Spring Street Silver Spring, MD 20910 (Addre
April 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number
April 30, 2025	EX-99.1	Three Months Ended March 31, Dollar Change Percentage Change 2025 2024 Total revenues $ 794.4 $ 677.7 $ 116.7 17 % Net income $ 322.2 $ 306.6 $ 15.6 5 % Net income, per basic share $ 7.18 $ 6.52 $ 0.66 10 % Net income, per diluted share $ 6.63 $ 6.17 Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports First Quarter 2025 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 30, 2025: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-
April 30, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commis
April 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registran UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) o Defin
April 29, 2025	DEF 14A	DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) x Defin
April 28, 2025	EX-10.1	Credit Agreement, dated as of April 25, 2025, among the Registration, the lenders referred to therein, and Wells Fargo Bank, National Association, as administrative agent and as a swingline lender, incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on April 28, 2025 Exhibit 10.1 Execution Version $2,500,000,000 CREDIT AGREEMENT dated as of April 25, 2025 by and among UNITED THERAPEUTICS CORPORATION, as Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER PARTY HERETO, as Guarantors, THE LENDERS REFERRED TO HEREIN, as Lenders, BANK OF AMERICA, N.A., DNB MARKETS, INC., JPMORGAN CHASE BANK, N.A., PNC BANK, NATIONAL ASSOCIATION and U.S. BANK NATIONAL ASSOCIATION, as co
April 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 United Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris
February 26, 2025	EX-10.28	Employee Directors in 2025 and thereafter under the United Therapeutics Corporation 2015 Stock Incentive Plan. Exhibit 10.28 UNITED THERAPEUTICS CORPORATION GRANT NOTICE FOR 2015 STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTIONS FOR NON-EMPLOYEE DIRECTORS FOR GOOD AND VALUABLE CONSIDERATION, United Therapeutics Corporation (the “Company”), hereby grants to Participant named below the nonqualified stock option (the “Option”) to purchase any part or all of the number of shares of its par value common stock (th
February 26, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 United Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Com
February 26, 2025	EX-19	nsider Trading Policy Exhibit 19 UNITED THERAPEUTICS CORPORATION AND SUBSIDIARIES STATEMENT OF COMPANY POLICY Securities Trades by Company Personnel United Therapeutics Corporation (the “Company”) has adopted this policy on insider trading (this “Policy”), which applies to each officer, director and employee of the Company or any of its subsidiaries, in order to reduce the risk of securities laws violations that could have severe civil and criminal consequences.
February 26, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeu
February 26, 2025	EX-21	Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF THE REGISTRANT IVIVA Medical, Inc., a Delaware corporation Lung Bioengineering Inc., a Delaware corporation Miromatrix Medical Inc., a Delaware corporation Revivicor, Inc., a Delaware corporation United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Wales United Therapeutics Ireland Limited, a company incorporated under the laws of Irelan
February 26, 2025	EX-99.1	Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 Total revenues $ 735.9 $ 614.7 $ 2,877.4 $ 2,327.5 Net income $ 301.3 $ 217.1 $ 1,195.1 $ 984.8 Net income, per basic share $ 6.74 $ 4.62 $ 26.44 $ 21.04 Net income, per dilu Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., February 26, 2025: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a r
February 10, 2025	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of United Therapeutics Corporation is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
January 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 United Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur
January 13, 2025	EX-99.1	United Therapeutics: Enabling Inspiration J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 13, 2025 2 INTRODUCTION Safe Harbor Statement MIROKIDNEY®, MIROLIVERELAP®, ORENITRAM®, REMODULIN®, TYVASO®, and TYVASO DPI® are registered trademarks of United Therap Exhibit 99.1 United Therapeutics: Enabling Inspiration J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 13, 2025 2 INTRODUCTION Safe Harbor Statement MIROKIDNEY®, MIROLIVERELAP®, ORENITRAM®, REMODULIN®, TYVASO®, and TYVASO DPI® are registered trademarks of United Therapeutics Corporation and/or its subsidiaries. UHEART™, UKIDNEY™, ULOBE™, ULUNG™, and UTHYMOKIDNEY™ are trademarks of United Therapeutics Co
November 8, 2024	SC 13G/A	UTHR / United Therapeutics Corporation / ROTHBLATT MARTINE A - SC 13G/A Passive Investment SC 13G/A 1 tm2427864d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 6) United Therapeutics Corporation (Name of Issuer) Common Stoc
October 30, 2024	EX-99.1	Three Months Ended September 30, Dollar Change Percentage Change 2024 2023 Total revenues $ 748.9 $ 609.4 $ 139.5 23 % Net income $ 309.1 $ 267.6 $ 41.5 16 % Net income, per basic share $ 6.93 $ 5.71 $ 1.22 21 % Net income, per diluted share $ 6.39 $ Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Third Quarter 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., October 30, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent
October 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file num
October 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 United Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Comm
October 16, 2024	SC 13G	UTHR / United Therapeutics Corporation / STATE STREET CORP Passive Investment SC 13G 1 UnitedTherapeuticsCorp.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* UNITED THERAPEUTICS CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 91307C102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule
July 31, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0
July 31, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commiss
July 31, 2024	EX-99.1	Three Months Ended June 30, Dollar Change Percentage Change 2024 2023 Total revenues $ 714.9 $ 596.5 $ 118.4 20 % Net income $ 278.1 $ 259.2 $ 18.9 7 % Net income, per basic share $ 6.26 $ 5.53 $ 0.73 13 % Net income, per diluted share $ 5.85 $ 5.24 Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Second Quarter 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2024. Total revenues in the second quarter of 2024 grew 20 percent year-
July 31, 2024	EX-10.2	eventh Amendment to Specialty Pharmacy Network Agreement, dated as of June 7, 2024, between the Registrant and Accredo Health Group, Inc. Exhibit 10.2 SEVENTH AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Seventh Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referr
July 31, 2024	EX-10.3	fth Amendment to Wholesale Product Purchase Agreement, dated as of Jun Exhibit 10.3 Twelfth Amendment To Wholesale Product Purchase Agreement THIS TWELFTH AMENDMENT TO WHOLESALE PRODUCT PURCHASE AGREEMENT (this “Twelfth Amendment”) is made as of the date the last Party executes this Twelfth Amendment (the “Amendment Effective Date”), by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation ha
July 31, 2024	EX-FILING FEES	Filing Fee Table* Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) TABLE 1 – NEWLY REGISTERED SECURITIES Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.
July 31, 2024	S-8	As filed with the Securities and Exchange Commission on July 31, 2024 As filed with the Securities and Exchange Commission on July 31, 2024 Registration No.
June 27, 2024	EX-10.1	nited Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan, incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed June 27, 2024 Exhibit 10.1 UNITED THERAPEUTICS CORPORATION AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN (effective June 26, 2024) 1. Purpose The purpose of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (this “Plan”) is to advance the interests of United Therapeutics Corporation (the “Company”) by stimulating the efforts of employees, officers, non-employee directors and ot
June 27, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 United Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd
June 27, 2024	EX-99.1	For Immediate Release Exhibit 99.1 For Immediate Release United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 27, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the addition of former Minnesota Commissioner of Health Jan Malcolm to its Board of Directors. Ms. Malcolm was electe
June 10, 2024	SC 13G/A	UTHR / United Therapeutics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: United Therapeutics Corp Title of Class of Securities: Common Stock CUSIP Number: 91307C102 Date of Event Which Requires Filing of this Statement: May 31, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
May 31, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdiction of File Number) Identification Number) Incorporation or Organization) 1000 Spring Street Silver Spring, MD 20910 (Addre
May 1, 2024	EX-99.1	Three Months Ended March 31, Dollar Change Percentage Change 2024 2023 Total revenues $ 677.7 $ 506.9 $ 170.8 34 % Net income $ 306.6 $ 240.9 $ 65.7 27 % Net income, per basic share $ 6.52 $ 5.20 $ 1.32 25 % Net income, per diluted share $ 6.17 $ 4.8 Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports First Quarter 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 1, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-ove
May 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number
May 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 United Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commissio
April 29, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registran UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) o Defin
April 29, 2024	DEF 14A	DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) x Defin
April 29, 2024	DEF 14A	DEFINITIVE PROXY STATEMENT About United Therapeutics Our company was founded over 27 years ago with the challenge of finding a way to cure or treat a rare, life-threatening illness suffered by our CEO's daughter.
March 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 United Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris
March 25, 2024	EX-99.1	For Immediate Release Exhibit 99.1 For Immediate Release United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program Repurchase reflects the strength of United Therapeutics’ balance sheet and confidence in its near-term prospects SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 25, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced
March 25, 2024	EX-10.1	Master Confirmation – Accelerated Share Repurchase, between the Company and Citi, dated March 25, 2024 Exhibit 10.1 EXECUTION VERSION United Therapeutics Corporation 1000 Spring Street Silver Spring MD 20910 Attention: James Edgemond, Chief Financial Officer and Treasurer Re: Accelerated Share Repurchase Ladies and Gentlemen: This master confirmation (this “Master Confirmation”), dated as of March 25, 2024 is intended to set forth certain terms and provisions of certain Transactions (each, a “Trans
March 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 United Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris
February 27, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 United Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd
February 21, 2024	EX-97	cs Corporation Clawback Poli Exhibit 97 UNITED THERAPEUTICS CORPORATION CLAWBACK POLICY Adopted July 12, 2023 Recoupment of Incentive-Based Compensation It is the policy of United Therapeutics Corporation (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s consolidated financial statements (including any required accounting restatement to correct an error in previou
February 21, 2024	EX-99.2	For Immediate Release Exhibit 99.2 For Immediate Release United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process SILVER SPRING, Md., and RESEARCH TRIANGLE PARK, N.C., February 21, 2024 - United Therapeutics Corporation (Nasdaq: UTHR) announced today the commencement of litigation with the United States Food and Drug Administration (FDA). In the litigation, United Therapeutics alleges that
February 21, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeu
February 21, 2024	EX-4.2	Description of Securities Registered under Section 12 of the Exchange Act Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 United Therapeutics Corporation has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the Exchange Act): Common Stock, par value $0.01 per share (common stock). All references in this document to United Therapeutics, o
February 21, 2024	EX-10.59	Sixth Amendment to Specialty Pharmacy Network Agreement, dated as of November 7, 2023, between the Registrant and Accredo Health Group, Inc. Exhibit 10.59 SIXTH AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Sixth Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred
February 21, 2024	EX-99.1	Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Total revenues $ 614.7 $ 491.5 $ 2,327.5 $ 1,936.3 Net income $ 217.1 $ 132.1 $ 984.8 $ 727.3 Net income, per basic share $ 4.62 $ 2.88 $ 21.04 $ 15.98 Net income, per dilute Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., February 21, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a r
February 21, 2024	EX-21	Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF THE REGISTRANT IVIVA Medical, Inc., a Delaware corporation Lung Bioengineering Inc., a Delaware corporation Lung Biotechnology PBC, a Delaware public benefit corporation Miromatrix Medical Inc., a Delaware corporation Revivicor, Inc., a Delaware corporation United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Wales United Therapeutics Ir
February 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 United Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Com
February 21, 2024	EX-10.52	Eleventh Amendment to Wholesale Product Purchase Agreement, dated as of November 3, 2023, by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, and the Registrant Exhibit 10.52 Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Eleventh Amendment To Wholesale Product Purchase Agreement This Eleventh Amendment to Wholesale Product Purchase Agreement (this “Eleventh Amendment”) is made as of the date the last Party executes this Eleventh A
February 14, 2024	SC 13G/A	UTHR / United Therapeutics Corporation / Avoro Capital Advisors LLC - UNITED THERAPEUTICS CORPORATION Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* United Therapeutics Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 91307C102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule
February 14, 2024	SC 13G/A	UTHR / United Therapeutics Corporation / ROTHBLATT MARTINE A - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.
February 13, 2024	SC 13G/A	UTHR / United Therapeutics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02159-unitedtherapeuticsco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: United Therapeutics Corp Title of Class of Securities: Common Stock CUSIP Number: 91307C102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box
February 8, 2024	SC 13G/A	CELU / Celularity Inc. / UNITED THERAPEUTICS Corp - SC 13G/A Passive Investment SC 13G/A 1 tm245374d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 ) Celularity Inc. (Name of Issuer) Common Stock, $0.0001 par v
February 8, 2024	SC 13G/A	UTHR / United Therapeutics Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* UNITED THERAPEUTICS Corp (Name of Issuer) Common Stock (Title of Class of Securities) 91307C102 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
December 22, 2023	SC 13D	MIRO / Miromatrix Medical Inc / UNITED THERAPEUTICS Corp - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Miromatrix Medical Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 60471P108 (CUSIP Number) John S. Hess, Jr., Esq. Executive Vice President and Deputy General Counsel United Therapeutics Corporation 1735 Connecticut Avenue, N.W
December 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 United Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju
December 13, 2023	EX-99.(A)(5)(E)	Joint Press Release issued on December 13, 2023. Exhibit (a)(5)(E) For Immediate Release United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger SILVER SPRING, Md.
December 13, 2023	CORRESP	Abu Dhabi · Beijing · Brussels · Century City · Dallas · Denver · Dubai · Frankfurt · Hong Kong · Houston · London · Los Angeles Munich · New York · Orange County · Palo Alto · Paris · Riyadh · San Francisco · Singapore · Washington, D.C. Gibson, Dunn & Crutcher LLP 1050 Connecticut Avenue, N.W. Washington, D.C. 20036-5306 Tel 202.955.8500 gibsondunn.com Stephen Glover Direct: +1 202.955.8593 Fax: +1 202.530.9598 [email protected] VIA EDGAR December 13, 2023 Brian Soares, Special Counsel Christina Chalk, Assistant Chief U.S. Securities and Exchange Commission Division of Corporation Finance Office of Mergers & Acquisitions 10
December 13, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3) MIROMATRIX MEDICAL INC. (Name of Subject Company — UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3) MIROMATRIX MEDICAL INC. (Name of Subject Company — Issuer) MORPHEUS SUBSIDIARY INC. a wholly owned subsidiary of UNITED THERAPEUTICS CORPORATION (Names of Filing Persons — Offerors) Common Stock, par v
December 12, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) MIROMATRIX MEDICAL INC. (Name of Subject Company — UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) MIROMATRIX MEDICAL INC. (Name of Subject Company — Issuer) MORPHEUS SUBSIDIARY INC. a wholly owned subsidiary of UNITED THERAPEUTICS CORPORATION (Names of Filing Persons — Offerors) Common Stock, par v
December 12, 2023	EX-99.(A)(5)(D)	Joint Press Release issued on December 12, 2023. Exhibit (a)(5)(D) For Immediate Release United Therapeutics and Miromatrix Medical Announce Successful Tender Offer SILVER SPRING, Md.
December 4, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) MIROMATRIX MEDICAL INC. (Name of Subject Company — UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) MIROMATRIX MEDICAL INC. (Name of Subject Company — Issuer) MORPHEUS SUBSIDIARY INC. a wholly owned subsidiary of UNITED THERAPEUTICS CORPORATION (Names of Filing Persons — Offerors) Common Stock, par v
December 4, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table SCHEDULE TO-T (Rule 14d-100) Miromatrix Medical Inc.
November 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 United Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju
November 13, 2023	EX-99.(A)(1)(F)	on November 13, 2023 (incorporated by reference to Exhibit (a)(1)(F) to the Schedule TO filed November 13, 2023). Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).
November 13, 2023	EX-99.(A)(1)(C)	Form of Notice of Guaranteed Delivery. Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY for Tender of Common Shares of MIROMATRIX MEDICAL INC.
November 13, 2023	EX-99.(A)(1)(D)	Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.* Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of MIROMATRIX MEDICAL INC.
November 13, 2023	EX-FILING FEES	Filing Fee Table* Exhibit 107 Calculation of Filing Fee Table SCHEDULE TO-T (Rule 14d-100) Miromatrix Medical Inc.
November 13, 2023	SC TO-T	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 MIROMATRIX MEDICAL INC. (Name of Subject Company — Issuer) MORPHEUS S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 MIROMATRIX MEDICAL INC. (Name of Subject Company — Issuer) MORPHEUS SUBSIDIARY INC. a wholly owned subsidiary of UNITED THERAPEUTICS CORPORATION (Names of Filing Persons — Offerors) Common Stock, par value $0.00001 per
November 13, 2023	EX-99.(A)(1)(B)	Form of Letter of Transmittal (including Internal Revenue Service Form W-9). Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of MIROMATRIX MEDICAL INC.
November 13, 2023	EX-99.(A)(1)(E)	Form of Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.* Exhibit (a)(1)(E) Offer to Purchase All Outstanding Shares of Common Stock of MIROMATRIX MEDICAL INC.
November 13, 2023	EX-99.(A)(1)(A)	Offer to Purchase, dated November 13, 2023. TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of MIROMATRIX MEDICAL INC.
November 1, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file num
November 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 United Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Comm
November 1, 2023	EX-10.1	, 2023, between the Registrant and Accredo Health Group, Inc., incorporated by reference to Exhibit 10. Exhibit 10.1 FIFTH AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Fifth Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred t
November 1, 2023	EX-99.1	Three Months Ended September 30, Dollar Change Percentage Change 2023 2022 Total revenues $ 609.4 $ 516.0 $ 93.4 18 % Net income $ 267.6 $ 239.3 $ 28.3 12 % Net income, per basic share $ 5.71 $ 5.26 $ 0.45 9 % Net income, per diluted share $ 5.38 $ 4 Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Third Quarter 2023 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., November 1, 2023: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2023. Total revenues in the third quarter of 2023 grew 18% year-o
November 1, 2023	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Miromatrix Medical Inc. (Name of Subject Company — Issuer) Morpheus S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Miromatrix Medical Inc. (Name of Subject Company — Issuer) Morpheus Subsidiary Inc. a wholly owned subsidiary of United Therapeutics Corporation (Names of Filing Persons — Offerors) Common Stock, par value $0.00001 per
November 1, 2023	EX-99.1	Excerpts from Transcript of United Therapeutics Corporation’s Q3 Earning Call held on November 1, 2023 (incorporated by reference to Exhibit 99.1 to the Schedule TO-C filed by United Therapeutics Corporation with the SEC on November 1, 2023). Exhibit 99.1 The following are excerpts from the transcript of United Therapeutics’ Q3 2023 earnings call held on November 1, 2023: Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer: Also, earlier this week, we announced an agreement to acquire publicly traded Miromatrix Medical, a company focused on ending the waiting list for organ transplantation. Miromatrix utilizes an organ ma
October 30, 2023	EX-99.1	Joint press release issued by United Therapeutics Corporation and Miromatrix Medical Inc., dated October 30, 2023 (incorporated by reference to Exhibit 99.1 to the Schedule TO-C filed by United Therapeutics Corporation with the SEC on October 30, 2023). Exhibit 99.1 For Immediate Release United Therapeutics to Acquire Miromatrix Medical SILVER SPRING, Md., RESEARCH TRIANGLE PARK, N.C., and EDEN PRAIRIE, Minn., October 30, 2023 - United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused
October 30, 2023	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Miromatrix Medical Inc. (Name of Subject Company — Issuer) Morpheus S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Miromatrix Medical Inc. (Name of Subject Company — Issuer) Morpheus Subsidiary Inc. a wholly owned subsidiary of United Therapeutics Corporation (Names of Filing Persons — Offerors) Common Stock, par value $0.00001 per
October 30, 2023	EX-99.1	United Therapeutics Corporation Investor FAQ, dated October 30, 2023 (incorporated by reference to Exhibit 99.1 to the Schedule TO-C filed by United Therapeutics Corporation with the SEC on October 30, 2023) Exhibit 99.1 United Therapeutics Investor FAQ Pending Acquisition of Miromatrix Medical, Inc. October 30, 2023 Why is United Therapeutics acquiring Miromatrix? Miromatrix is another shot on goal for our objective of creating an unlimited supply of tolerable, transplantable organs. This transaction would complement our capabilities in the organ manufacturing space and expand our early-stage pipelin
October 30, 2023	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Miromatrix Medical Inc. (Name of Subject Company — Issuer) Morpheus S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Miromatrix Medical Inc. (Name of Subject Company — Issuer) Morpheus Subsidiary Inc. a wholly owned subsidiary of United Therapeutics Corporation (Names of Filing Persons — Offerors) Common Stock, par value $0.00001 per
August 2, 2023	EX-99.1	Three Months Ended June 30, Dollar Change Percentage Change 2023 2022 Total revenues $ 596.5 $ 466.9 $ 129.6 28 % Net income $ 259.2 $ 116.0 $ 143.2 123 % Net income, per basic share $ 5.53 $ 2.56 $ 2.97 116 % Net income, per diluted share $ 5.24 $ 2 Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Second Quarter 2023 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., August 2, 2023: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2023. Total revenues in the second quarter of 2023 grew 28% year-over-y
August 2, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commis
August 2, 2023	S-8	As filed with the Securities and Exchange Commission on August 2, 2023 As filed with the Securities and Exchange Commission on August 2, 2023 Registration No.
August 2, 2023	EX-10.2	, 2023, between the Registrant and Accredo Health Group, Inc., incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended Exhibit 10.2 FOURTH AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Fourth Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred
August 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0
August 2, 2023	EX-FILING FEES	Filing Fee Table* Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) TABLE 1 – NEWLY REGISTERED SECURITIES Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.
July 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 United Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd
July 24, 2023	EX-99.1	For Immediate Release Exhibit 99.1 For Immediate Release United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 24, 2023 - United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation Unit
July 14, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.
July 10, 2023	SC 13G/A	UTHR / United Therapeutics Corp / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* UNITED THERAPEUTICS Corp (Name of Issuer) Common Stock (Title of Class of Securities) 91307C102 (CUSIP Number) June 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
June 28, 2023	EX-10.1	United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan Exhibit 10.1 UNITED THERAPEUTICS CORPORATION AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN (effective June 26, 2023) 1. Purpose The purpose of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (this “Plan”) is to advance the interests of United Therapeutics Corporation (the “Company”) by stimulating the efforts of employees, officers, non-employee directors and ot
June 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 United Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd
May 31, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdiction of File Number) Identification Number) Incorporation or Organization) 1040 Spring Street Silver Spring, MD 20910 (Addre
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 United Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commissio
May 3, 2023	EX-10.1	, by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, and the Registrant, incorporated by reference to Exhibit 10. Exhibit 10.1 Tenth Amendment To Wholesale Product Purchase Agreement This Tenth Amendment to Wholesale Product Purchase Agreement (this “Tenth Amendment” is made as of the date the last Party executes this Tenth Amendment (the “Amendment Effective Date”), by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation having offi
May 3, 2023	EX-10.2	, between the Registrant and Accredo Health Group, Inc., incorporated by reference to Exhibit 10. Exhibit 10.2 THIRD AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Third Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred t
May 3, 2023	EX-99.1	UNITED THERAPEUTICS CORPORATION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS CORPORATION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 3, 2023: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year
May 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number
April 28, 2023	DEF 14A	DEFINITIVE PROXY STATEMENT .11 11 United Therapeutics C O R P O R A T I O N A Public Benefit Corporation Notice of Annual Meeting of Shareholders and Proxy Statement About United Therapeutics Our company was founded over 26 years ago with the challenge of finding a way to cure or treat a rare, life-threatening illness suffered by our CEO's daughter. That mission continues today, has grown to encompass a variety of rare dise
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 21, 2023	EX-3.1	Tenth Amended and Restated Bylaws of the Registrant, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed April 21, 2023 Exhibit 3.1 TENTH AMENDED AND RESTATED BYLAWS OF UNITED THERAPEUTICS CORPORATION (A PUBLIC BENEFIT CORPORATION) ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of United Therapeutics Corporation, a public benefit corporation organized under the laws of the State of Delaware (the “Corporation”), shall be in the State of Delaware at such location and with such registered agen
April 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 United Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris
March 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 United Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris
February 22, 2023	EX-10.37	Form of Grant Notice and Standard Terms and Conditions for Stock Options Granted to Employees (Performance Vesting) under the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (applicable to performance-based stock options granted on or after March 15, 2023) Exhibit 10.37 UNITED THERAPEUTICS CORPORATION GRANT NOTICE FOR 2015 STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTIONS FOR EMPLOYEES (PERFORMANCE VESTING) FOR GOOD AND VALUABLE CONSIDERATION, United Therapeutics Corporation (the “Company”), hereby grants to Participant named below the nonqualified stock option (the “Option”) to purchase any part or all of the number of shares of its par value common
February 22, 2023	EX-10.38	Form of Grant Notice and Standard Terms and Conditions for Restricted Stock Units Granted to Employees (Performance Vesting) under the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (applicable to performance-based restricted stock units granted on or after March 15, 2023) Exhibit 10.38 UNITED THERAPEUTICS CORPORATION GRANT NOTICE FOR 2015 STOCK INCENTIVE PLAN RESTRICTED STOCK UNITS FOR EMPLOYEES (PERFORMANCE VESTING) FOR GOOD AND VALUABLE CONSIDERATION, United Therapeutics Corporation (the “Company”), hereby grants to Participant named below the restricted stock units (the “Award”) with respect to the number of shares of its par value common stock (the “Shares”), t
February 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 United Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Com
February 22, 2023	EX-21	Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Lung Bioengineering Inc., a Delaware corporation Lung Biotechnology PBC, a Delaware public benefit corporation Revivicor, Inc., a Delaware corporation United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Wales United Therapeutics Ireland Limited, a company incorporated under the laws of Ireland Unither Biotech Inc., a Cana
February 22, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeu
February 22, 2023	EX-99.1	UNITED THERAPEUTICS CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., February 22, 2023: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2022. Full year total revenues ros
February 14, 2023	SC 13G/A	UTHR / United Therapeutics Corporation / Avoro Capital Advisors LLC - UNITED THERAPEUTICS CORPORATION Passive Investment SC 13G/A 1 p23-0578sc13ga.htm UNITED THERAPEUTICS CORPORATION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* United Therapeutics Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 91307C102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of T
February 9, 2023	SC 13G/A	UTHR / United Therapeutics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02126-unitedtherapeuticsco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: United Therapeutics Corp. Title of Class of Securities: Common Stock CUSIP Number: 91307C102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box
February 6, 2023	SC 13G	UTHR / United Therapeutics Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* United Therapeutics Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 91307C102 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
February 6, 2023	SC 13G/A	CELU / Celularity Inc. Class A / UNITED THERAPEUTICS Corp - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.
February 3, 2023	SC 13G/A	CELU / Celularity Inc. Class A / UNITED THERAPEUTICS Corp - SC 13G/A Passive Investment SC 13G/A 1 tm234873d1sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1) Celularity Operations Inc. (Name of Issuer) Common Stock, $0.0
February 3, 2023	SC 13G	CELU / Celularity Inc. Class A / UNITED THERAPEUTICS Corp - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.
February 2, 2023	SC 13G/A	VGG8959N1069 / Tottenham Acquisition I Limited / UNITED THERAPEUTICS Corp - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.
February 2, 2023	SC 13G/A	UTHR / United Therapeutics Corporation / ROTHBLATT MARTINE A - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.
January 17, 2023	SC 13G/A	VGG8959N1069 / Tottenham Acquisition I Limited / UNITED THERAPEUTICS Corp - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 United Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juri
January 9, 2023	EX-99.1	UTHR: A Public Benefit Corporation \| January 2023 \| 1 United Therapeutics: Enabling Inspiration J.P. Morgan 41 st Annual Healthcare Conference EX-99.1 2 tm232645d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 UTHR: A Public Benefit Corporation \| January 2023 \| 1 United Therapeutics: Enabling Inspiration J.P. Morgan 41 st Annual Healthcare Conference UTHR: A Public Benefit Corporation \| January 2023 \| 2 Safe Harbor Statement This presentation contains forward - looking statements which represent United Therapeutics’ expectations or beliefs regardi
November 2, 2022	EX-99.1	United Therapeutics Corporation Reports Third Quarter 2022 Financial Results Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports Third Quarter 2022 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., November 2, 2022: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 3
November 2, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file num
November 2, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 United Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Comm
October 11, 2022	EX-99.1	UNITED THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 3 TETON 2 STUDY OF TYVASO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS Second registration study of Tyvaso® (treprostinil) Inhalation Solution for patients with IPF Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 3 TETON 2 STUDY OF TYVASO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS Second registration study of Tyvaso® (treprostinil) Inhalation Solution for patients with IPF SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., October 11, 2022: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit
October 11, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 United Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur
September 20, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer J
September 1, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juri
September 1, 2022	EX-99.1	United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation Exhibit 99.1 United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation SILVER SPRING, Md., and RESEARCH TRIANGLE PARK, N.C., August 31, 2022 ? United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics? U.S. pate
August 9, 2022	CORRESP	M e d i c i n e s   F o r   L i f e ® 1040 Spring Street Silver Spring, MD 20910 tel 301.608.9292 fax 301.608.9291 August 9, 2022 SUBMITTED VIA EDGAR Division of Corporate Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attn: Christie Wong and Daniel Gordon Re: United Therapeutics Corporation Form 10-K for the Fiscal Year Ended December 31, 2021 Filed February 24
August 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commis
August 3, 2022	EX-99.1	United Therapeutics Corporation Reports Second Quarter 2022 Financial Results Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports Second Quarter 2022 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., August 3, 2022: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 202
August 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0
August 3, 2022	EX-10.3	Second Amendment to Specialty Pharmacy Network Agreement, dated as of June 13, 2022, between the Registrant and Accredo Health Group, Inc., incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Exhibit 10.3 SECOND AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This Second Amendment to Specialty Pharmacy Network Agreement (this “Amendment”) is made as of the date the last Party executes this Amendment (the “Amendment Effective Date”), by and between Accredo Health Group, Inc. (“Specialty Pharmacy”), and United Therapeutics Corporation (“UT”). Specialty Pharmacy and UT are each referred
August 3, 2022	EX-FILING FEES	Filing Fee Table* EX-FILING FEES 4 tm2222193d1ex-filingfees.htm EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) TABLE 1 – NEWLY REGISTERED SECURITIES Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pr
August 3, 2022	EX-10.1	License and Collaboration Agreement, dated as of September 3, 2018, by and between the Registrant and MannKind Corporation, incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, for the quarter ended June 30, 2022. Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
August 3, 2022	S-8	As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No.
June 28, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd
June 28, 2022	EX-10.1	United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan Exhibit 10.1 UNITED THERAPEUTICS CORPORATION AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN (effective June 27, 2022) 1. Purpose The purpose of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (this ?Plan?) is to advance the interests of United Therapeutics Corporation (the ?Company?) by stimulating the efforts of employees, officers, non-employee directors and ot
May 31, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdiction of File Number) Identification Number) Incorporation or Organization) 1040 Spring Street Silver Spring, MD 20910 (Addre
May 24, 2022	EX-99.1	United Therapeutics Announces FDA Approval of Tyvaso DPI™ First approval of a dry powder inhaler for treatment of PAH and PH-ILD DPI device represents a convenient option for administration of treprostinil therapy Commercial launch activities underwa Exhibit 99.1 United Therapeutics Announces FDA Approval of Tyvaso DPI? First approval of a dry powder inhaler for treatment of PAH and PH-ILD DPI device represents a convenient option for administration of treprostinil therapy Commercial launch activities underway; patient availability expected in June 2022 SILVER SPRING, Md., and RESEARCH TRIANGLE PARK, N.C., May 24, 2022 ? United Therapeutics Co
May 24, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdi
May 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number
May 4, 2022	EX-99.1	United Therapeutics Corporation Reports First Quarter 2022 Financial Results Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports First Quarter 2022 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 4, 2022: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022.
May 4, 2022	EX-10.1	First Amendment to Specialty Pharmacy Network Agreement, dated as of February 16, 2022, between the Registrant and Accredo Health Group, Inc., incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. Exhibit 10.1 FIRST AMENDMENT TO SPECIALTY PHARMACY NETWORK AGREEMENT This First Amendment to Specialty Pharmacy Network Agreement (this ?Amendment?) is made as of the date the last Party executes this Amendment (the ?Amendment Effective Date?), by and between Accredo Health Group, Inc. (?Specialty Pharmacy?), and United Therapeutics Corporation (?UT?). Specialty Pharmacy and UT are each referred t
May 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commissio
April 29, 2022	DEF 14A	DEFINITIVE PROXY STATEMENT
April 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
April 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 22, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris
April 1, 2022	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris
April 1, 2022	EX-10.1	Credit Agreement, dated as of March 31, 2022, among the Registrant, certain of its subsidiaries party thereto, as guarantors, the lenders referred to therein, and Wells Fargo Bank, National Association, as administrative agent and as a swingline lender, incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on April 1, 2022. ? Exhibit 10.1 ? Execution Version ? ? ? $2,000,000,000 ? CREDIT AGREEMENT ? dated as of March 31, 2022 ? by and among ? UNITED THERAPEUTICS CORPORATION, as Borrower, ? CERTAIN SUBSIDIARIES OF THE BORROWER PARTY HERETO, as Guarantors, ? THE LENDERS REFERRED TO HEREIN, as Lenders, ? BANK OF AMERICA, N.A., DNB CAPITAL LLC, MUFG Bank, Ltd., and PNC BANK, NATIONAL ASSOCIATION, as co-Syndication Agents
February 24, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeu
February 24, 2022	EX-4.2	Act, incorporated by reference to Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2021. Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 United Therapeutics Corporation has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the Exchange Act): Common Stock, par value $0.01 per share (common stock). All references in this document to United Therapeutics, o
February 24, 2022	EX-99.1	United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results Double-digit percentage revenue and patient count growth in full-year 2021 Company reaffirms target to reach 6,000 patients with Tyvaso by the end of 2022 Maj Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results Double-digit percentage revenue and patient count growth in full-year 2021 Company reaffirms target to reach 6,000 patients with Tyvaso by the end of 2022 Major amendment to Tyvaso DPI? NDA pushes FDA deci
February 24, 2022	EX-10.57	Ninth Amendment to Wholesale Product Purchase Agreement, dated as of October 6, 2021, by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, and the Registrant, incorporated by reference to Exhibit 10.57 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2021. Exhibit 10.57 Ninth Amendment To Wholesale Product Purchase Agreement This Ninth Amendment to Wholesale Product Purchase Agreement (this ?Ninth Amendment? is made as of the date the last Party executes this Ninth Amendment (the ?Amendment Effective Date?), by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation having off
February 24, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Com
February 24, 2022	EX-21	Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Lung Bioengineering Inc., a Delaware corporation Lung Biotechnology PBC, a Delaware public benefit corporation Revivicor, Inc., a Delaware corporation United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Wales Unither Biotech Inc., a Canadian company Unither Bioelectronics, Inc., a Canadian company Unither Pharma, LLC, a D
February 11, 2022	SC 13G/A	UTHR / United Therapeutics Corporation / Avoro Capital Advisors LLC - UNITED THERAPEUTICS CORPORATION Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* United Therapeutics Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 91307C102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule
February 10, 2022	SC 13G/A	UTHR / United Therapeutics Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: United Therapeutics Corp. Title of Class of Securities: Common Stock CUSIP Number: 91307C102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi
February 4, 2022	SC 13G/A	UTHR / United Therapeutics Corporation / ROTHBLATT MARTINE A - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.
February 4, 2022	SC 13G	CELU / Celularity Inc. Class A / UNITED THERAPEUTICS Corp - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.
January 18, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur
January 14, 2022	SC 13G/A	VGG8959N1069 / Tottenham Acquisition I Limited / UNITED THERAPEUTICS Corp - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.
December 27, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju
November 3, 2021	EX-99.1	United Therapeutics Corporation Reports Third Quarter 2021 Financial Results Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports Third Quarter 2021 Financial Results SILVER SPRING, MD. and RESEARCH TRIANGLE PARK, N.C., November 3, 2021: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announce
November 3, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Comm
November 3, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file num
October 18, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur
October 18, 2021	EX-99.1	United Therapeutics Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application Draft label contains both PAH and PH-ILD indications; no contraindications and no boxed warning Complete response cites an open inspection issue at a third Exhibit 99.1 For Immediate Release United Therapeutics Provides an Update on the Progress of the Tyvaso DPI? New Drug Application Draft label contains both PAH and PH-ILD indications; no contraindications and no boxed warning Complete response cites an open inspection issue at a third-party analytical testing facility; no other deficiencies cited Approval and launch expected in summer 2022 or earl
October 1, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer J
October 1, 2021	EX-10.1	Form of Indemnification Agreement between the Registrant and each of its Directors and Executive Officers, incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed October 1, 2021. Exhibit 10.1 FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?), dated as of , is made by and between UNITED THERAPEUTICS CORPORATION, a Delaware public benefit corporation (the ?Company?), and (the ?Indemnitee?), an ?agent? (as hereinafter defined) of the Company. RECITALS A. The Company recognizes that competent and experienced persons are increasingly reluctant
October 1, 2021	EX-3.1	Restated Certificate of Incorporation of the Registrant, incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed October 1, 2021 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF UNITED THERAPEUTICS CORPORATION (A PUBLIC BENEFIT CORPORATION) It is hereby certified that: 1. The present name of the corporation (hereinafter called the ?corporation?) is United Therapeutics Corporation. The name under which the corporation was originally incorporated was Lung Rx, Inc.; and the date of filing the original certificate of incorp
September 10, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
August 19, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
August 19, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registr UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
August 19, 2021	DEF 14A	DEFINITIVE PROXY STATEMENT
August 4, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
August 4, 2021	S-8	Form S-8 (No. 333-258434) filed with the Securities and Exchange Commission on August 4, 2021 As filed with the Securities and Exchange Commission on August 4, 2021 Registration No.
August 4, 2021	EX-99.1	United Therapeutics Corporation Reports Second Quarter 2021 Financial Results Tyvaso® (treprostinil) Inhalation Solution net revenue growth of 29% year over year; total net revenue growth of 23% year over year Tyvaso DPI™ NDA under review with FDA ac Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports Second Quarter 2021 Financial Results Tyvaso? (treprostinil) Inhalation Solution net revenue growth of 29% year over year; total net revenue growth of 23% year over year Tyvaso DPI? NDA under review with FDA action expected in October 2021 SILVER SPRING, MD
August 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0
August 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commis
July 14, 2021	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
June 25, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd
June 25, 2021	EX-10.1	United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan Exhibit 10.1 UNITED THERAPEUTICS CORPORATION AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN (effective June 25, 2021) 1. Purpose The purpose of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (this ?Plan?) is to advance the interests of United Therapeutics Corporation (the ?Company?) by stimulating the efforts of employees, officers, non-employee directors and ot
June 23, 2021	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd
June 17, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
June 16, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd
June 16, 2021	EX-99.1	UNITED THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF TYVASO DPI™ NEW DRUG APPLICATION FOR PRIORITY REVIEW FDA action expected in October 2021 Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF TYVASO DPI? NEW DRUG APPLICATION FOR PRIORITY REVIEW FDA action expected in October 2021 SILVER SPRING, Md., and RESEARCH TRIANGLE PARK, N.C., Wednesday, June 16, 2021 ? United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the Ne
June 7, 2021	EX-99.1	UNITED THERAPEUTICS PURSUES NEW CLAIMS FOR TRADE SECRET MISAPPROPRIATION AGAINST LIQUIDIA Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS PURSUES NEW CLAIMS FOR TRADE SECRET MISAPPROPRIATION AGAINST LIQUIDIA SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Monday, June 7, 2021: United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc. (a subsidiary of Liquidia Cor
June 7, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdi
June 3, 2021	EX-99.1	UNITED THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 3 TETON STUDY OF TYVASO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS First pivotal study of Tyvaso® (treprostinil) Inhalation Solution outside pulmonary hypertension Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 3 TETON STUDY OF TYVASO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS First pivotal study of Tyvaso? (treprostinil) Inhalation Solution outside pulmonary hypertension SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Thursday, June 3, 2021: United Therapeutics Corporation (Nasdaq: UTHR) announced t
June 3, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdi
June 1, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisdiction of File Number) Identification Number) Incorporation or Organization) 1040 Spring Street Silver Spring, MD 20910 (Addre
May 5, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number
May 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Commissio
May 5, 2021	EX-99.1	United Therapeutics Corporation Reports First Quarter 2021 Financial Results Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug Application (NDA) subm Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] United Therapeutics Corporation Reports First Quarter 2021 Financial Results Tyvaso? (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI? New Drug Application (NDA) submitted to U.S. Food and Drug Administration TETO
April 29, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 29, 2021	DEFA14A	- DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 29, 2021	DEF 14A	DEFINITIVE PROXY STATEMENT
April 29, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registran Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
April 19, 2021	EX-99.1	UNITED THERAPEUTICS ANNOUNCES SUBMISSION OF TYVASO DPI™ NEW DRUG APPLICATION TO FDA NDA submission includes both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease indications Priority review voucher Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES SUBMISSION OF TYVASO DPI™ NEW DRUG APPLICATION TO FDA NDA submission includes both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease indications Priority review voucher applied to the NDA submission SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Monday, April 19, 2021: United T
April 19, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Juris
April 1, 2021	EX-99.1	United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease First and only approved therapy in the United States for patients with PH-ILD, a serious, life-thre Exhibit 99.1 For Immediate Release United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with potentially more than 30,000 patients in need FDA approval based on data from the INCREASE cli
April 1, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd
March 3, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jurisd
March 1, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Se SC 13G/A 1 tm218268d1sc13ga.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. ) United Therapeutics Corporation (Name of Issuer) Common
February 24, 2021	EX-4.2	Description of Securities Registered under Section 12 of the Exchange Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 United Therapeutics Corporation (?United Therapeutics?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our Common Stock, par value $0.01 per share (our ?common stock?). DESCRIPTION OF COMMON
February 24, 2021	EX-99.1	UNITED THERAPEUTICS CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS Exhibit 99.1 For Immediate Release Contact: Dewey Steadman Phone: (202) 919-4097 Email: [email protected] UNITED THERAPEUTICS CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS Silver Spring, MD and Research Triangle Park, NC, February 24, 2021: United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31,
February 24, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-263
February 24, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-26301 52-1984749 (State or Other Jurisdiction of Incorporation) (Com
February 24, 2021	EX-21	Subsidiaries of the Registrant. Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Lung Bioengineering Inc., a Delaware corporation Lung Biotechnology PBC, a Delaware public benefit corporation Revivicor, Inc., a Delaware corporation SteadyMed Ltd., an Israeli company SteadyMed Therapeutics, Inc., a Delaware corporation United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Wales Unither Biotech Inc., a Ca
February 12, 2021	SC 13G	United Therapeutics Corporation SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* United Therapeutics Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 91307C102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu
February 10, 2021	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: United Therapeutics Corp. Title of Class of Securities: Common Stock CUSIP Number: 91307C102 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is fi
February 10, 2021	EX-99.1	UNITED THERAPEUTICS ANNOUNCES COMMERCIAL LAUNCH OF THE REMUNITY® PUMP FOR REMODULIN® Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES COMMERCIAL LAUNCH OF THE REMUNITY® PUMP FOR REMODULIN® SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Wednesday, February 10, 2021: United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the innovative Remunity® Pump for Remodulin® for patients with pulmonary arterial hypertensio
February 5, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur
February 5, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Se UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.
February 5, 2021	EX-3.1	Ninth Amended and Restated Bylaws of the Registrant, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed February 5, 2021. Exhibit 3.1 NINTH AMENDED AND RESTATED BYLAWS OF UNITED THERAPEUTICS CORPORATION ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of United Therapeutics Corporation (the “Corporation”) shall be in the State of Delaware at such location and with such registered agent in charge thereof as may be established by the Board of Directors from time to time. Section 1.2. Other Office
January 28, 2021	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur
January 28, 2021	EX-99.1	UNITED THERAPEUTICS ANNOUNCES BREEZE STUDY OF INVESTIGATIONAL TYVASO DPI™ MEETS PRIMARY OBJECTIVE Study demonstrated safety and tolerability of Tyvaso DPI™ in patients with PAH transitioning from Tyvaso® Inhalation Solution A separate study in health Exhibit 99.1 UNITED THERAPEUTICS ANNOUNCES BREEZE STUDY OF INVESTIGATIONAL TYVASO DPI™ MEETS PRIMARY OBJECTIVE Study demonstrated safety and tolerability of Tyvaso DPI™ in patients with PAH transitioning from Tyvaso® Inhalation Solution A separate study in healthy volunteers demonstrated comparable treprostinil exposure between Tyvaso DPI and Tyvaso Inhalation Solution Tyvaso DPI NDA filing antici
January 22, 2021	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur
January 13, 2021	EX-99.1	United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease INCREASE Study is First to Demonstrate a Clear Benefit in Patients Exhibit 99.1 For Immediate Release United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments Company to host a webcast detaili
January 13, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur
January 8, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Se UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.
December 28, 2020	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2020 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Ju
December 28, 2020	EX-99.1	UNITED THERAPEUTICS ANNOUNCES AGREEMENT TO ACQUIRE PRIORITY REVIEW VOUCHER Voucher expected to be applied to the forthcoming NDA for Tyvaso DPI™ Exhibit 99.1 For Immediate Release UNITED THERAPEUTICS ANNOUNCES AGREEMENT TO ACQUIRE PRIORITY REVIEW VOUCHER Voucher expected to be applied to the forthcoming NDA for Tyvaso DPI™ SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Monday, December 28, 2020: United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV
December 23, 2020	CORRESP	* * * 1735 Connecticut Ave., NW Washington, DC 20009 tel 202.483.7000 fax 202.483.4005 December 23, 2020 SUBMITTED VIA EDGAR Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission Washington, D.C. 20549 Attention: Dorrie Yale Suzanne Hayes Li Xiao Brian Cascio Re: United Therapeutics Corporation Form 10-K for the Fiscal Year Ended December 31, 2020 Filed
December 9, 2020	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2020 United Therapeutics Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 000-26301 52-1984749 (State or Other (Commission (I.R.S. Employer Jur
December 9, 2020	EX-99.1	United Therapeutics Receives FDA Orphan Drug Designation for TREPROSTINIL for the Treatment of Idiopathic Pulmonary Fibrosis Phase 3 TETON study planned in 2021 for Tyvaso® in patients with idiopathic pulmonary fibrosis Exhibit 99.1 For Immediate Release For Further Information Contact: Dewey Steadman at (202) 919-4097 Email: [email protected] United Therapeutics Receives FDA Orphan Drug Designation for TREPROSTINIL for the Treatment of Idiopathic Pulmonary Fibrosis Phase 3 TETON study planned in 2021 for Tyvaso® in patients with idiopathic pulmonary fibrosis SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Wedn

UTHR / United Therapeutics Corporation - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

मूलभूत आँकड़े

SEC Filings

SEC Filings (Chronological Order)

Other Listings

MX:UTHR
DE:UTH	€323.50